Piia Mikkonen

UPM (Finland) — Finland

Medicine · Health Sciences

9h-index313citations36works1.62yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(11), Cancer Cells and Metastasis(8), 3D Printing in Biomedical Research(6), Cancer Research and Treatments(6), Cancer Genomics and Diagnostics(5)

Publications36 total

Soft matrix promotes immunosuppression in tumor-resident immune cells via COX-FGF2 signaling
Nature Communications·2025· 4 citedOpen Access
Distinct molecular profiles and shared drug vulnerabilities in pancreatic metastases of renal cell carcinoma
Communications Biology·2024· 2 citedOpen Access
P01-70 3D liver models in animal-free nanofibrillar cellulose hydrogels
Toxicology Letters·2024
A Facile, Transfection‐Free Approach to siRNA Delivery in In Vitro 3D Spheroid Models
Current Protocols·2024· 2 citedOpen Access
Abstract B036: Micromechanical regulation of tumor immune microenvironment
Cancer Research·2024
Distinct Molecular Profiles and Drug Vulnerabilities in Pancreatic Metastases of Renal Cell Carcinoma
2023Open Access
Data from Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum–Taxane Chemotherapy
2023Open Access
Supplementary Figures 1 - 9, Tables 1 - 6 from Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum–Taxane Chemotherapy
2023Open Access
Data from Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum–Taxane Chemotherapy
2023Open Access
Supplementary Figures 1 - 9, Tables 1 - 6 from Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum–Taxane Chemotherapy
2023Open Access
Comparison of two supporting matrices for patient-derived cancer cells in 3D drug sensitivity and resistance testing assay (3D-DSRT)
SLAS DISCOVERY·2023· 15 citedOpen Access
Protocol for 3D drug sensitivity and resistance testing of patient-derived cancer cells in 384-well plates
SLAS DISCOVERY·2022· 7 citedOpen Access
Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status
Frontiers in Oncology·2022· 11 citedOpen Access
Avidin-Conjugated Nanofibrillar Cellulose Hydrogel Functionalized with Biotinylated Fibronectin and Vitronectin Promotes 3D Culture of Fibroblasts
Biomacromolecules·2021· 13 citedOpen Access
ALDH1A1‐related stemness in high‐grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR‐PI3K/aurora kinase inhibitors
The Journal of Pathology·2019· 53 citedOpen Access
Next generation sequencing for cancer precision medicine
2019
Abstract 2945: Clinical implementation of precision systems oncology in the treatment of ovarian cancer based on ex-vivo drug testing and molecular profiling
Cancer Research·2019· 2 cited
Abstract 2945: Clinical implementation of precision systems oncology in the treatment of ovarian cancer based on ex-vivo drug testing and molecular profiling
Experimental and Molecular Therapeutics·2019· 2 cited
A conversational robotic lab assistant for automated microfluidic 3d microtissue production
2019
NGS compatible streamlined DNA recovery from 3D cell cultures in GrowDex
Työväentutkimus Vuosikirja·2018Open Access
page 1 of 2Next →

Frequent Co-authors

Katja Kaipio(15), Olli Carpén(15), Annika Auranen(13), Vilja Pietiäinen(12), Kaisa Huhtinen(12), Johanna Hynninen(12), Seija Grénman(10), Sampsa Hautaniemi(10), Olli Kallioniemi(10), Swapnil Potdar(8), Viljami Aittomäki(8), Rony Lindell(8), Rainer Lehtonen(8), Päivi Östling(6), Pia Roering(6), Krister Wennerberg(6), Astrid Murumägi(6), Ping Chen(5), Pekka Ellonen(5), Teijo Pellinen(5)